MedTrace Logo

Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD0328 in Elderly Healthy Subjects

NCT00687141 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2010-12-10

No results posted yet for this study

Summary

The primary purpose of this study is to investigate the safety and tolerability of AZD0328 following once-daily dosing for 13 days in elderly healthy volunteers and to define maximum tolerated dose.

Conditions

Interventions

DRUG

AZD0328

Oral solution administered orally once per day on day 1, and then day 3 through to day 14. Specific dose depends on dose panel.

DRUG

Placebo

Administered orally as a solution once per day on day 1, and then day 3 through to day 14.

Sponsors & Collaborators

Principal Investigators

  • Wolfgang Kühn · Quintiles ABStrandbodgatan 1S-753 23 Uppsala

  • Erik Eliasson, MD, PhD · AstraZeneca R&D SödertäljeMedical Science S-151 85 Södertälje Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
60 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-11-30
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • Sweden

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00687141 on ClinicalTrials.gov